Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Government In Dilemma As DCGI's Competence Is Questioned Amid Mounting Criticism

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - An eerie uncertainty looms over the future of India's highest and most powerful drug authority, the Drug Controller General of India, as the government was challenged last week against its decision to grant a nine-month service term extension to the present incumbent Surinder Singh

You may also be interested in...



Graft Charges At India State Drug Controller’s Office Lead To Multiple Transfers

As news of fresh corruption charges cloud efforts for transparency in India’s licensing process, several high-profile officials are learned to have been moved in a brisk clean-up exercise by the health ministry.

Powerful Parliamentary Committee Slams India’s Drug Regulator; Calls For Swift Overhaul

The committee unravels a system full of questionable practices and recommends complete overhaul of India’s drug regulator.

R&D Funding, Epidemiology And Balanced Policies To Fuel India Growth - CII Lifescience Conclave

NEW DELHI - Establishment of a new global disease detection center for epidemiology studies in India, a unique government funding method to boost innovation, and academic partnerships were among the prominent discussion topics at the Annual LifeScience Conclave, organized by the Confederation of Indian Industry in the capital city

Related Content

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel